Cabozantinib is a anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
It inhibits the following receptor tyrosine kinases (RTKs): c-Met (HGFR), VEGFR2, AXL, RET, and FLT3.
Cabozantinib is used in two forms. A capsule form (Cometriq) is used to treat medullary thyroid cancer and a tablet form (Cabometyx) is used to treat renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma.
